TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 781231
Drug: Aspirin (3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.9 gm/day)
Study: 26382562
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser adjunct treatment (1.0 W power, pulsed mode, λ 810 nm, energy density 3 J/cm², time 1 min, power density 400 mW/cm², energy 1.5 J, spot diameter 1 mm)
Study: 25046945
Drug: Chinese Compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Compound Shenhuang Ointment (CSO)
Study: 17026493
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 (BIAsp30)
Study: 20460999
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (30 ml)
Study: 20460999
Drug: Ropivacaine 0.375%
Normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.375% (20 ml)
Study: 20460999
Drug: Ropivacaine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 20 ml (ED(concentration)50/ED(concentration)95)
Study: 20460999
Drug: Ropivacaine doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine doses
Study: 16378790
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of electronic and direct detailing
Study: 9527978
Drug: OMC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC (omeprazole 20 mg b.i.d., metronidazole 500 mg b.i.d., clarithromycin 500 mg b.i.d.)
Study: 9527978
Drug: OMA (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMA (omeprazole 20 mg b.i.d., metronidazole 500 mg b.i.d., amoxycillin 1 g b.i.d.)
Study: 911706
Drug: Iron+folate supplements
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron+folate supplements
Study: 23929659
Drug: Darexaban 20
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 20 mg
Study: 23929659
Drug: Darexaban 120
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 120 mg
Study: 23929659
Drug: Darexaban 240
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 240 mg
Study: 19631122
Drug: Stromal hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stromal hydration with balanced salt solution
Study: 10982755
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg risedronate (n = 255)
Study: 10982755
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate (n = 260)
Study: 27799644
Drug: CHoBI7 intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHoBI7 intervention (handwashing with soap and water treatment during hospital stay and home visits)
Study: 17380213
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate and atorvastatin calcium single-pill combination (5 or 10 mg amlodipine and 10 mg atorvastatin)
Study: 17380213
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate and atorvastatin calcium single-pill combination
Study: 10233185
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg b.d. orally
Study: 8966140
Drug: Intravenous 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 25% magnesium sulphate infusion (20 ml dissolved in 500 ml 5% dextrose for 60 minutes)
Study: 28599949
Drug: Quetiapine-ER (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine-ER (600 mg/day)
Study: 28599949
Drug: Aripiprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (20 mg/day)
Study: 20632462
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol therapy (ET)
Study: 21366801
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A/B vaccine
Study: 10706965
Drug: Monovalent hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent hepatitis B vaccine
Study: 3754834
Drug: Defibrotide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (800 mg daily, 200 mg intravenously 4 times a day for 7 days)
Study: 2450026
Drug: sotalol 160
Normalized name: sotalol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol 160 mg b.d.
Study: 2450026
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 mg b.d.
Study: 31033008
Drug: Preoperative Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Extracorporeal Shockwave Therapy (ESWT)
Study: 29909374
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy for Command Hallucinations (CTCH)
Study: 24346114
Drug: Dexamphetamine (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (0.45 mg/kg, per os)
Study: 9078541
Drug: Glutamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.2 g.kg‐1.d‐1 on the day of the study) supplemented formula
Study: 8104348
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg haloperidol i.v. for 3 days followed by 3 x 5 mg haloperidol p.o./d
Study: 8104348
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 100 mg perazin p.o./d
Study: 3743144
Drug: Placebo bronchodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bronchodilator
Study: 3743144
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol and placebo
Study: 26125285
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of soy isoflavones (60 mg) administered concomitantly with levothyroxine
Study: 26125285
Drug: Levothyroxine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine administered 6 hours after soy isoflavones
Study: 23147689
Drug: Beta-blockers (BB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (BB) therapy for 12 weeks
Study: 20879881
Drug: Immunotherapy (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 with GM-CSF and interleukin-2)
Study: 20879881
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (six cycles of isotretinoin)
Study: 18575771
Drug: Topical sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sucralfate (SUC‐LIS 95) applied daily for a median period of 42.0 days
Study: 18575771
Drug: Topical sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sucralfate (SUC‐LIS 95)
Study: 11409190
Drug: Fluoxetine drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine drops
Study: 11409190
Drug: Marketed fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed fluoxetine capsules
Study: 8210919
Drug: etodolac SR
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etodolac SR 400 mg once daily (q.d.)
Study: 8210919
Drug: etodolac SR
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etodolac SR 600 mg once daily (q.d.)
Study: 8210919
Drug: etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 200 mg twice daily (b.i.d.)
Study: 8210919
Drug: etodolac 300
Normalized name: etodolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 300 mg twice daily (b.i.d.)
Study: 3513715
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 2 mg/kg/day in two divided doses for five days
Study: 28301043
Drug: Topical Treatment
Normalized name: Topicale
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Treatment Optimization Programme (TTOP)
Study: 23784346
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) 500 mg oral single dose
Study: 21690118
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral weight loss treatment (FBT)
Study: 19559476
Drug: Eflornithine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine (400 mg/kg per day, every 6 h) for 14 days
Study: 19559476
Drug: Nifurtimox-eflornithine combination
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox-eflornithine combination therapy (NECT): Eflornithine (400 mg/kg per day, every 12 h) for 7 days with oral Nifurtimox (15 mg/kg per day, every 8 h) for 10 days
Study: 11063062
Drug: In-depth computerized
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-depth computerized assessment administered by an interviewer
Study: 11063062
Drug: Self-administered audio-computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered audio-computer assisted interview
Study: 9284898
Drug: L-arginine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (0.5 g/min in the last 60 minutes of the clamp)
Study: 9284898
Drug: D-arginine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-arginine (0.5 g/min in the last 60 minutes of the clamp)
Study: 7951278
Drug: Analgesic 1
Normalized name: CVS Hemorrhoidal & Analgesic 1% Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic 1 at two dosage levels
Study: 7951278
Drug: Analgesic 2
Normalized name: Leader Oral Analgesic 20% Maximum Strength Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic 2 at two dosage levels
Study: 3300436
Drug: Nebulized bitolterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized bitolterol solution, 2.5 mg three times a day for 1 month
Study: 3300436
Drug: Nebulized isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized isoproterenol solution, 2.5 mg three times a day for 1 month
Study: 30273922
Drug: Quadriceps strengthening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadriceps strengthening program (3 times weekly)
Study: 25677679
Drug: QVA149 110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50 µg once daily
Study: 25677679
Drug: TIO 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO 18 µg once daily + FOR 12 µg twice daily
Study: 23305631
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg plus DMARDs
Study: 18343646
Drug: Salmeterol/fluticasone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone combination (SFC) 50/250 microg
Study: 14633181
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with interferon alpha 2b 5 million units (MU) subcutaneously (s.c.) daily for 8 weeks
Study: 14633181
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with interferon alpha 2b 5 MU s.c. three times a week (TIW) for 8 weeks
Study: 14633181
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms received ribavirin (1000-1200 mg orally per day) starting at week 4
Study: 9154538
Drug: Original formulation
Normalized name: Zegerid (Original Formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original formulation of amoxicillin/clavulanate potassium (Augmentin) administered tid for 10 days (40/10 mg/kg/day)
Study: 9154538
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of amoxicillin/clavulanate potassium (Augmentin) administered bid for 10 days (45/6.4 mg/kg/day)
Study: 9154538
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of amoxicillin/clavulanate potassium (Augmentin) administered bid for 5 days (45/6.4 mg/kg/day)
Study: 2670309
Drug: Plain tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tablets of pyronaridine (0.5 g on day 1, 0.3 g on day 2)
Study: 2670309
Drug: Enteric-coated tablets
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablets of pyronaridine (0.4 g x 2 on day 1, 0.4 g on day 2)
Study: 779663
Drug: Loperamide 2
Normalized name: loperamide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 2 mg capsules
Study: 28324167
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg subcutaneous injection every 4 weeks
Study: 22149065
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (800 IU) and Calcium (2 g)
Study: 18495735
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg every 6 weeks through week 96
Study: 18495735
Drug: Infliximab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab 7.5 mg/kg (after dose escalation starting at week 36)
Study: 8944402
Drug: alprazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam (0.5 and 1 mg)
Study: 21603892
Drug: alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam (1 mg)
Study: 8944402
Drug: alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam (1 mg) and lorazepam (2 mg)
Study: 1956688
Drug: sulphate quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphate quinine (30 mg/kg bw/day in three divided doses)
Study: 1956688
Drug: fansidar (sulphadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: fansidar (sulphadoxine 20-30 mg/kg bw/day, single dose)
Study: 6111670
Drug: Cefazolin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (5 days of antibiotic prophylaxis, starting just before surgery)
Study: 30676542
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patch (TFP) 25 μg/h applied 14 hours before operation
Study: 30676542
Drug: Intravenous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous continuous fentanyl (25 μg/h) with loading dose (25 μg) in control group
Study: 25958101
Drug: Fibrinolytic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic group (streptokinase 250,000 IU in 50 ml saline)
Study: 25958101
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (50 ml saline)
Study: 23648056
Drug: High-dose ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ropivacaine (3mg/kg)
Study: 23648056
Drug: Low-dose ropivacaine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ropivacaine (1.5mg/kg)
Study: 16283925
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light treatment (8,500 Lux) for one hour a day
Study: 16283925
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light treatment (<10 Lux) for one hour a day
Study: 16283925
Drug: Placebo (dim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dim red light treatment)
Study: 12817911
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEpo) treatment
Study: 8904622
Drug: Minaprine 100
Normalized name: minaprine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine 100 mg once daily
Study: 8904622
Drug: Minaprine 200
Normalized name: minaprine
DrugBank: Minaprine (DB00805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine 200 mg once daily
Study: 8904622
Drug: Minaprine 300
Normalized name: minaprine
DrugBank: Minaprine (DB00805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine 300 mg once daily
Study: 8904622
Drug: Amitriptyline 150
Normalized name: amitriptyline 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 150 mg once daily (75 mg during the first week)
Study: 31340956
Drug: Integrated GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated GP care plus treatment as usual (includes GP training in cognitive behavioural skills, GP supervision, and written/audio-visual materials for GPs and participants)
Study: 27223813
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine plus cisplatin
Study: 18536386
Drug: Xianglingwan administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xianglingwan administered from the fifth day of the menstrual cycle for 3 weeks every month for three months
Study: 10875786
Drug: Tuberculosis vaccine
Normalized name: Tuberculosis vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculosis vaccine (exact details not specified)
Study: 6653131
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of orphenadrine (35 mg) and paracetamol (450 mg) tablets, 1 tablet 3 times daily
Study: 30340939
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen (oestradiol hemihydrate patches)
Study: 30340939
Drug: Oral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestrogen (oestradiol valerate pills)
Study: 26903143
Drug: Home-based robot-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based robot-guided therapy
Study: 26903143
Drug: Laboratory-based robot-guided
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laboratory-based robot-guided therapy
Study: 9448170
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., colloidal bismuth subcitrate 120 mg q.i.d. for 7 days
Study: 9448170
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d. for 7 days
Study: 31419353
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group (ATG, n = 13)
Study: 31419353
Drug: Passive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive treatment group (PTG, n = 13)
Study: 30635159
Drug: SBC-103 (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBC-103 (5.0 mg/kg)
Study: 30635159
Drug: SBC-103 (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBC-103 (10.0 mg/kg)
Study: 23640009
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch alone (control condition)
Study: 23640009
Drug: Bupropion augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion augmentation of the patch
Study: 21832964
Drug: Oral sea
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sea buckthorn oil (2 g daily for 3 months)
Study: 21832964
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil (2 g daily for 3 months)
Study: 16989377
Drug: Amoxicillin added
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin added to treatment
Study: 16989377
Drug: Hearing test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hearing test before and after treatment
Study: 3485757
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg X d‐1)
Study: 3485757
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg X d‐1)
Study: 31410672
Drug: SRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP with photodynamic therapy (670 nm)
Study: 22752384
Drug: GSK1521498 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 5 mg/day
Study: 20220282
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (40 min, once a day for 8 days)
Study: 11390728
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g oral administration)
Study: 9232130
Drug: Intravenous phenylephrine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phenylephrine, 50‐200 micrograms/min, titrated to a 20% increase in mean arterial blood pressure
Study: 9232130
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO), 40 ppm
Study: 9232130
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phenylephrine and NO
Study: 2901302
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg oral pyridostigmine
Study: 26810442
Drug: Energy‐dense formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy‐dense formula (Calogen Extra, Nutricia) 30 mL distributed 3 times daily for 6 weeks
Study: 23391814
Drug: WBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT + SRS + TMZ (75 mg/m(2)/day × 21 days)
Study: 23391814
Drug: WBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT + SRS + ETN (150 mg/day)